15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.6B | -$517M | 50.9% | -30.2% | -$31M | $727M | $235M |
| 2024 | $1.6B | -$7M | 54.8% | 1.8% | $25M | $760M | $246M |
| 2023 | $1.5B | $68M | 57.4% | 7.2% | $73M | $775M | $276M |
| 2022 | $1.6B | $181M | 62.3% | 15.3% | $222M | $775M | $457M |
| 2021 | $1.5B | $169M | 61.2% | 12.8% | $264M | $844M | $513M |
| 2020 | $1.4B | $134M | 62.0% | 11.0% | $165M | $878M | $470M |
| 2019 | $1.5B | $50M | 62.8% | 6.2% | $162M | $878M | $199M |
| 2018 | $1.5B | $61M | 61.2% | 7.5% | $122M | $900M | $139M |
| 2017 | $1.2B | $65M | 63.3% | 3.8% | $71M | — | $175M |
| 2016 | $992M | $75M | 64.8% | 11.6% | $69M | — | $102M |
| 2015 | — | -$4M | — | — | $71M | — | $48M |
| 2014 | — | $34M | — | — | $45M | — | $72M |
| 2013 | — | -$21M | — | — | $11M | — | $121M |
| 2012 | — | $41M | — | — | -$10M | — | $97M |
| 2011 | — | $28M | — | — | $66M | — | $101M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $392M | -$5M | 55.4% | 2.9% | -$5M | $717M | $237M |
| Dec '25 | $435M | -$2M | 50.8% | 5.3% | -$5M | $727M | $235M |
| Sep '25 | $402M | -$5M | 51.5% | 2.9% | $26M | $736M | $232M |
| Jun '25 | $416M | -$484M | 50.4% | -123.4% | -$11M | $746M | $218M |
| Mar '25 | $383M | -$25M | 50.8% | -4.0% | -$40M | $756M | $239M |
| Dec '24 | $443M | $19M | 56.3% | 8.0% | $21M | $760M | $246M |
| Sep '24 | $381M | -$11M | 52.6% | -2.1% | -$7M | $765M | $215M |
| Jun '24 | $418M | -$12M | 54.0% | -0.7% | $11M | $770M | $215M |
| Mar '24 | $369M | -$3M | 56.1% | 1.1% | $291000 | $775M | $592M |
| Dec '23 | $397M | $20M | 57.0% | 9.1% | $34M | $775M | $276M |
| Sep '23 | $382M | $19M | 57.1% | 7.0% | $14M | $775M | $274M |
| Jun '23 | $381M | $4M | 54.3% | 3.3% | $13M | $775M | $309M |
| Mar '23 | $381M | $24M | 61.1% | 9.6% | $12M | $775M | $307M |
| Dec '22 | $398M | $53M | 62.8% | 17.0% | $71M | $775M | $457M |
| Sep '22 | $385M | $50M | 61.5% | 16.9% | $59M | $810M | $512M |
| Jun '22 | $398M | $45M | 62.7% | 15.0% | $57M | $821M | $447M |
| Mar '22 | $377M | $33M | 62.1% | 12.3% | $35M | $833M | $407M |
| Dec '21 | $406M | $45M | 61.5% | 14.4% | $42M | $844M | $513M |
| Sep '21 | $387M | $43M | 62.7% | 14.6% | $75M | $855M | $470M |
| Jun '21 | $390M | $35M | 61.2% | 13.3% | $85M | $866M | $397M |
How the market has priced IART against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Integra Lifesciences Holdings Corp's revenue has grown 3.6% per year. These are computed facts, not advice.
As of FY2025, Integra Lifesciences Holdings Corp reported $727M of total debt against $235M of cash; operating income covered interest expense -5.7×.
In FY2025, gross margin was 50.9%, operating margin -30.2%, and net margin -31.6%.
As of Jun '26, Integra Lifesciences Holdings Corp traded at a price-to-earnings ratio of about 28.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.